COVID-19: How Can China Help African Countries Have a Stake in the Race for a Vaccine?

 In analysis, op-ed

Six months after the emergence of COVID-19 in Wuhan, China, the global effort to develop appropriate vaccines and treatments is continuing at a pace. The WHO report that there are now 125 candidate vaccines in development, including 10 in clinical evaluation. In recent weeks, there has been controversy around the need for trials of vaccinations and treatments in African countries. But the debate so far misses a major part of the puzzle – whether Africans will ever hold intellectual property rights over whatever medicine or vaccines successfully make it through trials.

The original controversy began with a live TV discussion involving two French doctors discussing how and where to conduct vaccination trials. During the discussion, they suggested that, due to lower ethical constraints, trials should be undertaken in African countries. An outcry from many commentators decrying their suggestion ensued, culminating in a condemnation from the Director-General of the WHO in an April virtual press conference.

At the same time, the spotlight also revealed the shockingly low number of clinical trials for COVID-19-related research in Africa, whether that’s tests, treatments, or vaccines. Since the outcry, other scientists have pointed out that ethical clinical trials to research how different interventions impact different disease outcomes actually do need to be conducted across Africa’s diverse contexts, circumstances, and ethnicities – especially as many African countries suffer from significant and large disease burdens. With the current pandemic, the urgency of this issue is heightened, as explained well in a recent Lancet article.

Yet, at the time of writing, among the 1,556 interventional clinical trials related to COVID-19 listed on the WHO’s International Clinical Trials Registry Platform (ICTRP), only 38 include any African countries – that’s under 2.5% of the total. Those trials that do involve African countries are concentrated in only a few countries. 23 are in Egypt alone and 8 involve South Africa, with other trials also taking place in Nigeria, Ghana, Tunisia, Kenya, and Zambia. This suggests that, in over 40 African countries, no COVID-19 related trials are currently happening nor planned. These numbers compare poorly to 389 trials with Chinese involvement, and 59 trials with India.

The figures above are sadly nothing new – prior to COVID-19, despite the clear needs, under 5% of ICTRP-listed clinical trials typically involved African country participation. Efforts like the African Academy of Science’s Clinical Trials Community and the African Vaccines Regulatory Forum (AVAREF) aim to address and rectify this problem, while related new COVID-19 specific initiatives have been launched including the WHO’s Solidarity Trial, a host of African university responses, and the COVID-19 Clinical Research Coalition – which focuses on accelerating research on COVID-19 in resource-limited settings.

But All of These Discussions Miss a Critical Issue. Intellectual Property.

If anything is central to how the pharmaceutical industry across the world works, it is intellectual property. It is intellectual property that drives the race to do the trials and find a viable treatment or vaccine. For the industry, IP effectively acts as a short-term monopoly, granted to the pharma companies or scientific organizations as a reward for the successful innovation and production of clinically efficient medicines (the R&D for which can be prohibitively expensive).

A side effect of imposing IP rights can mean higher costs for patients needing lifesaving and other essential drugs and treatments – especially for those patients in developing countries, where a patent-holding manufacturer might be slow to (or might not at all) bring their product to the market. Is it fair that this might still be the case, even for citizens in countries where trials took place?

In recent years, this issue of access to medicines has been tackled through a process called “compulsory licensing”. It grants extra flexibility from current international IP protection laws under the World Trade Organisation to poorer countries to produce drugs. Countries such as South Africa have used these flexibilities for HIV and AIDS drugs, and even more recently for COVID-19 Chile and Israel have invoked them for COVID-19.

But this too misses the point.

Why Isn’t There Any Pharma-Related Intellectual Property Being Held in Poor Countries, Including African Countries?

While China’s pharma industry has had a much smaller global footprint than many other countries such as the UK, U.S. and even India, the experience of the Comoros, an African island nation, and its efforts against malaria with Chinese support, act as an interesting case study.

A decade or so ago, Artepharm, co-founded by Guangdong New South Group and Guangzhou University of Chinese Medicine, created and patented Artequick – a drug-based the Nobel prize-winning work of Tu Youyou, a Chinese pharmaceutical chemist who discovered artemisinin. Together with the Comorian authorities and grant aid from the Chinese Government, Artepharm implemented a dramatic plan to use the drug to eradicate malaria from (initially some smaller) Comorian islands, by employing the method of mass drug administration (MDA). Rather than treating symptoms of malaria, or simply trying to prevent mosquitos from transmitting malaria to humans with bed nets or DEET, MDA involves making the entire human population a hostile environment for the malaria parasite for a time period longer than its lifecycle. This process, involving three courses of Artequick over a month, led to spectacularly positive results – with an initial 98% decrease in the prevalence of malaria in the Comorian islands of Moheli and Ndzouani.

However, the program was not without controversy. Criticisms were made about the small involvement of local teams and a lack of open evaluation both before and after implementation – including with regard to side-effects. Crucially, the product used was only in phase 4 of development – which led to negative headlines like “China tests malaria drug on an entire African nation”.

Notwithstanding, the Comorian authorities and Chinese aid partners continued with the policy, extending it to the country’s largest island. The WHO’s annual World Malaria Reports show a steep decrease in Comorian malaria cases from tens of thousands per year from 2010-2013, down to under four thousand a year up until 2017. However, in 2018, the year for which WHO has most updated data, Comoros saw a huge increase of 587% in reported cases from 2274 in 2017 to 15,613 in 2018. This suggests that MDA of Artequick in the short term is not enough to eradicate malaria on the islands in the long run, but potential reasons for the increase include improved diagnosis and reporting, inadequate vector control, and climatic factors.

However, given the Comoros authorities’ involvement, the broader question was – what long-term value did Comoros get from the collaboration? Better health, yes, but Artepharm used its early successes in the Comoros to market and sell Artequick elsewhere in Africa and beyond. The Comorians did not benefit in the same way from these sales, and the knowledge gained from the “experiments”. The IP was held by the Chinese company and never in any part extended to the Comoros.

This is not a unique case. There are numerous other examples that involve companies from other pharma giants such as the U.S., UK, France, and Germany. There are also are many such collaborations taking place now between pharmaceutical companies from richer nations and African research institutions, including the provision of aid. For example, the British company working with a Senegalese institute to develop a 10 minute COVID19 rapid test received UK aid. The issue is that even with these cases, there has been little discussion or sharing of whether any of the IP rights for the treatments, drugs, or vaccines that result from this research will ever be extended to the countries within which trials took place.

Extending IP rights to African organizations would provide governments with new and stronger incentives to invest in medicinal and pharmaceutical R&D within their own countries, which in the long run could be transformational.

How Can We Make This Happen?

For several years, UNAIDS has been at the vanguard of encouraging a push towards local manufacturing of pharmaceutical and medical equipment in developing countries including much of Africa, aiming to both create jobs on the continent in production and keep pharmaceutical costs down for local health organizations and patients. Previously, the Beijing-based consultancy that I work for, Development Reimagined, collaborated with UNAIDS and the China Chamber of Commerce for Import and Export of Medicines and Health Products on a report highlighting such opportunities in 21 African countries.

UNAIDS, Unitaid, or another similar organisation, ideally with Chinese support, needs to take up a similar initiative to push with regards to intellectual property, especially as far as COVID-19 is concerned.

The COVID-19 patent pooling platform proposed by Costa Rica, due to launch this week, is a step in the right direction, as was the commitment from China’s leader Xi Jinping, at the virtual World Health Assembly, to make a COVID-19 vaccine, if developed by a Chinese organisation, a “global public good”. That hopefully (although it has not been clarified) means that it will be provided across the world for free, at least for a few years. But the long-term solution for African development in particular is not to just to make medicines relevant to Africans or give them out for free, whether as China aid or via the GAVI Alliance.

The long-term solution is to fully develop these medicines on the continent, and have African-owned organizations own the IP. Even just a small proportion of the proceeds and profits from IP would help African countries to meet the SDGs. That’s the controversy we need to start discussing.

By Peter Grinsted, Economist at Development Reimagined. This article was originally published on The China Africa Project Website on May 29th 2020.

Recommended Posts
pingbacks / trackbacks

Leave a Comment

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt


Research Analyst

Edmond is a research analyst who is passionate about sustainable development, innovation, and the environment. Passionate about climate financing, he firmly believe there is a more reliable system to promote equality, growth, and welfare in societies without affecting the ecosystem. Through his skills, knowledge and experienced gained over 7 years, he wants to make an impact in the world of development. Edmond holds a Master’s Degree in Public Policy from Korea Development Institute and a BA Degree (Honors) in Business from University of Derby.


    Founder and CEO

Hannah Ryder is the Founder & CEO of Development Reimagined. A former diplomat and economist with 20 years of experience, named one of 100 most influential Africans in 2021, she is also Senior Associate for the Africa Program of the Center for Strategic International Studies (CSIS), sits on the Board of the Environmental Defence Fund, and is a member of UAE's International Advisory Council on the New Economy. Prior to her role at DR, Ms Ryder led the United Nations Development Programme (UNDP)’s work with China to help it scale up and improve its cooperation with other developing countries, including in Africa. She has also played various advisory roles for the UN and OECD and co-authored the seminal Stern Review of the Economics of Climate Change in 2006.


Deputy Director

Leah Lynch is Deputy Director of Development Reimagined (DR), and head of the China office. Leah has over 10 years of experience in development and has lived in China for over 8 years. Leah has also travelled extensively around Asia and Africa for research. Leah supports the strategic direction of the team across China, with a mission to deliver high quality research on sustainable development and poverty reduction. Leah is also Chair of the Sustainability Forum at the British Chamber of Commerce in China, providing direction on sustainability initiatives for British and Chinese business. Leah has also consulted on various evaluations on UK aid (ICAI) and is a specialist on development cooperation from the UK and China. Leah has also consulted on various UN projects, including providing support to the UN China team during the COVID-19 Pandemic. Prior to DR, Leah was at the United Nations Development Programme (UNDP) China, supporting the UN’s portfolio on communication strategies, China’s South- South Cooperation and the Belt and Road Initiative (BRI). Before UNDP, Leah lived and worked in Kenya developing sustainable water policies for the Kenyan government.


China-Africa Policy Analyst

Yike Fu is a Policy Analyst and has been responsible for leading numerous areas of work, including on debt analysis in Africa and beyond, and China-Africa trade and investment logistics and analysis. She is the co-author of “African Debt Guide”, in which she challenged the narrative that Africa is in the midst of a new debt crisis by analysing data back to the 1970s and adopting new metrics to present the real story behind the data. She also developed a benchmark to compare the financial distribution of development partners such as the UK, US, Japan, France and China in Africa. Prior to her role at DR she worked at the International Finance Corporation and African Union Representational Mission to the US. She holds a Masters in International Affairs from George Washington University.


Research Analyst

Judith is a Research and Policy Analyst, where she specialises in Africa-China relations, international development, and diplomacy. During her time at Development Reimagined, Judith has co-authored several articles published in The Diplomat on debt and China-Barbados relations and was quoted by China Daily in a piece on Women Rights in China. Previously, Judith worked as a research analyst for an Advocate and Commissioner and Oats office in Kenya.


Policy Analyst

Ovigwe specialises in geopolitics with particular reference to Africa in a changing Global Order. He is adept at critically analysing the politics of contemporary development processes and providing insight into the geopolitical interests that influence them. His work includes research, publications, tailored briefings and advising on global and regional trends, and issues at the nexus of geopolitics and development. Ovigwe appears frequently in media around the world such as Al Jazeera, TRT World, SABC, CGTN, BBC Radio, and other platforms.


Policy Analyst

Jing leads China-African health and agriculture cooperation research at Development Reimagined, having managed our FOCAC Policy Analysis and Advocacy project. She is also the co-author of “China-Africa Health Cooperation under FOCAC Umbrella”, in which she analysed China’s commitments around health cooperation since the first FOCAC summit and deepdived into four African countries’ health overview, challenges and cooperation with China as cases studies. Before DR, Jing worked at GIZ Cambodia on M&E of a disability advocacy project. She also worked as a translator with Chinese medical team in Benin.


Trade Policy Analyst

Patrick is an International Trade Policy and Trade Law Expert with over 5 years of experience. His expertise includes trade law, trade policy analysis and regional integration. He is currently engaged with Development Reimagined as a Senior Trade Analyst and was the lead author of Development Reimagined's recent Report on Africa-China Relations titled "From China-Africa to Africa- China: A Blue Print for a Green and Inclusive Continent-Wide Strategy Towards China." and “Reimaging FOCAC Going Forward.” Patrick has previously consulted for the East African Community, UNECA and for the Kenya Ministry of Trade.


Senior Policy Analyst 

Rosemary is our Senior Policy Analyst. She is a skilled policy analyst and has previously worked as a UK civil servant. She is studying Human Rights at Birkbeck, University of London with a research focus on international law in the context of health crises such as the COVID-19 pandemic.


Project Manager and Africa-China Communication Assistant

Jade is a Project Manager for Development Reimagined’s flagship project Africa Unconstrained, which focuses on financing needs and debt vulnerabilities of African countries. Her research focuses on China-Africa development finance alongside debt vulnerabilities, infrastructure needs and South-South cooperation. She has worked with a breadth of stakeholders from China, Africa and the wider international community, including governments, private sector, NGOs and civil society. Her writing has appeared in a number of publications, including The Africa Report, The China-Africa Project, The Diplomat and more. Jade holds a Master’s in China and Globalisation studies from King’s College London.


Programme Manager

Rosie is the Project Manager of Africa Reimagined (AR) at Development Reimagined (DR) where she supports high-end African brands with entering the Chinese market by operating services such as trademark protection, Chinese market research, Chinese partnership building, and Africa to China logistical support and import/export services. Rosie has worked with DR for over two years now with proven success in helping high-end African brands navigate the Chinese market. She is extremely passionate about her work because more African brands selling in the Chinese marketplace means African countries can export MORE value-added goods, create MORE jobs and foster MORE innovation in African countries.

Rosie is also alumni of the School of International Studies at Peking University in Beijing where she is also an editor at the Peking Africa Think Tank. PATT is led by a diverse group of scholars who specialise in African Studies within the context of Sino-Africa relations.



Lauren has lived in six countries from the Americas to Europe and Asia and speaks both French and Spanish proficiently. At Development Reimagined, Lauren’s research focuses on climate action both in the Asia-Pacific and in Africa, and how countries are using tools such as SDGs and Covid-19 action to build a more climate-resilient future. She holds a Masters in International Relations from Leiden University.



Etsehiwot holds a Masters’s degree in Development Studies from the London School of Economics. She has diverse experience in humanitarian and development issues by working in both multilateral organizations and international non-governmental organizations. Etsehiwot is currently a consultant focusing on the SDGs and development finance.


Economist Consultant

Dibekulu is an economist by training. He holds an MSc in International Development Studies from Palacky University Olomouc, an MSc in Development Economics from the University of Clermont Auvergne, and an MSc in Economics, Finance, and International Integration from the University of Pavia. At Development Reimagined, he works as an Economist consultant. He has strong data analysis skills, with research interests centring around development finance, impact assessment, food security, and agricultural insurance.


Project Manager

Osaru is a health professional with an MSc in Health Systems Policy and an interest in women’s health and population management. At Development Reimagined, she applies her health sector experience to global health research and collating locally applicable development insights from China.


Research Analyst

Ferdinando’s research at Development Reimagined is centred on South-South Cooperation dynamics, specifically on the analysis of Chinese investment and debt flows in Africa and their linkages to African industrialisation. He is currently a Yenching Scholar at Peking University, after having graduated from the University of Cambridge with an MPhil in Development Studies.


Research Analyst

David is a Research and data analyst at Development Reimagined. His scholarly focus is mostly on interdisciplinary research in demographic economics and development with interests in migration, economic development and policy, education, health and subjective well-being. He is currently a PhD scholar at Nelson Mandela University from which he also holds Economics and Statistics and respectively.


Research Analyst Kenya

Ivory is a Kenyan lawyer with experience in policy research and analysis. She also supports the communications team at DR. Ivory speaks English, Swahili and French.


Research And Data Analyst China 

Joy Ene is a Research and Data Analyst at DR. Joy is passionate about African/global development, poverty eradication and trade policies between underdeveloped and developing countries. She is also a fourth-year student of International Economics and Trade at the  Liaoning University, Shenyang, China. She serves as the President of the Student Union, Liaoning University, International Students chapter.


Research Analyst 

Chensi Li is a research analyst. She has previously worked for local NGOs in Nigeria and Cameroon and think-tanks in China.  Her research areas include Sino-African relations, African foreign affairs, public diplomacy, state-building and national governance.

Yixin Yu

Research Analyst 

Yixin is a Junior Research Analyst and her focus areas is on public-private partnership and entrepreneurship. She has over three years of working experience in both private and public sectors in Ethiopia. She was the China Liaison Officer for project ‘Partnership for Investment and Growth in Africa’ at International Trade Centre, where she accumulated rich experience in investment and trade promotion


Founder and CEO

Hannah Ryder is the Founder & CEO of Development Reimagined. A former diplomat and economist with 20 years of experience, named one of 100 most influential Africans in 2021, she is also Senior Associate for the Africa Program of the Center for Strategic International Studies (CSIS), sits on the Board of the Environmental Defence Fund, and is a member of UAE's International Advisory Council on the New Economy. Prior to her role at DR, Ms Ryder led the United Nations Development Programme (UNDP)’s work with China to help it scale up and improve its cooperation with other developing countries, including in Africa. She has also played various advisory roles for the UN and OECD and co-authored the seminal Stern Review of the Economics of Climate Change in 2006.